Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AAPG Ascentage Pharma Group International	$41.13 -0.7%	$40.73	$16.50 ▼ $48.45	$3.82B	N/A	39,551 shs	2,554 shs
ACAD ACADIA Pharmaceuticals	$26.23 -1.3%	$23.22	$13.40 ▼ $26.65	$4.43B	0.7	2.18 million shs	2.17 million shs
GPCR Structure Therapeutics	$19.14 +0.7%	$19.11	$13.22 ▼ $45.37	$1.10B	-1.89	861,701 shs	429,948 shs
KRYS Krystal Biotech	$150.76 +2.1%	$145.15	$122.80 ▼ $207.84	$4.36B	0.7	328,890 shs	241,080 shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AAPG Ascentage Pharma Group International	-3.14%	-12.29%	+5.42%	+63.31%	+4,139,999,900.00%
ACAD ACADIA Pharmaceuticals	+3.30%	+6.54%	+17.46%	+19.20%	+68.70%
GPCR Structure Therapeutics	+0.96%	+2.32%	+4.00%	-15.25%	-53.74%
KRYS Krystal Biotech	+0.52%	+1.22%	-3.45%	+17.54%	-25.52%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AAPG Ascentage Pharma Group International	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ACAD ACADIA Pharmaceuticals	3.4135 of 5 stars	2.3	2.0	0.0	0.0	3.4	4.2	2.5
GPCR Structure Therapeutics	2.8687 of 5 stars	3.5	3.0	0.0	0.0	2.9	1.7	0.6
KRYS Krystal Biotech	4.7179 of 5 stars	3.5	1.0	0.0	4.7	2.6	3.3	2.5

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AAPG Ascentage Pharma Group International	3.00	Buy	N/A	N/A
ACAD ACADIA Pharmaceuticals	2.61	Moderate Buy	$28.88	9.27% Upside
GPCR Structure Therapeutics	3.00	Buy	$75.71	290.18% Upside
KRYS Krystal Biotech	3.00	Buy	$210.38	41.78% Upside

Current Analyst Ratings Breakdown

Latest GPCR, AAPG, KRYS, and ACAD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/22/2025	KRYS Krystal Biotech	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$219.00 ➝ $216.00
8/22/2025	KRYS Krystal Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$240.00
8/8/2025	ACAD ACADIA Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$32.00 ➝ $36.00
8/7/2025	ACAD ACADIA Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
8/7/2025	ACAD ACADIA Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sell ➝ Sell	$15.00 ➝ $17.00
8/7/2025	ACAD ACADIA Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$39.00 ➝ $40.00
8/7/2025	ACAD ACADIA Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$23.00 ➝ $24.00
8/7/2025	ACAD ACADIA Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$37.00 ➝ $38.00
8/7/2025	GPCR Structure Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$75.00 ➝ $60.00
8/7/2025	GPCR Structure Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$92.00 ➝ $90.00
8/7/2025	GPCR Structure Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$89.00 ➝ $87.00

(Data available from 8/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AAPG Ascentage Pharma Group International	$134.35M	28.78	N/A	N/A	$1.01 per share	41.19
ACAD ACADIA Pharmaceuticals	$1.02B	4.38	$0.72 per share	36.49	$4.87 per share	5.43
GPCR Structure Therapeutics	N/A	N/A	N/A	N/A	$13.40 per share	N/A
KRYS Krystal Biotech	$290.52M	14.78	$4.69 per share	31.67	$35.96 per share	4.13

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AAPG Ascentage Pharma Group International	-$55.54M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
ACAD ACADIA Pharmaceuticals	$226.45M	$1.33	19.91	34.77	6.55	21.80%	14.69%	9.41%	11/5/2025 (Estimated)
GPCR Structure Therapeutics	-$122.53M	-$1.05	N/A	N/A	N/A	N/A	-21.31%	-20.34%	11/12/2025 (Estimated)
KRYS Krystal Biotech	$89.16M	$4.92	30.16	14.72	N/A	40.85%	15.21%	13.81%	11/3/2025 (Estimated)

Latest GPCR, AAPG, KRYS, and ACAD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2025	Q2 2025	ACAD ACADIA Pharmaceuticals	$0.14	$0.16	+$0.02	$0.16	$263.07 million	$264.57 million
8/6/2025	Q2 2025	GPCR Structure Therapeutics	-$0.28	-$0.36	-$0.08	-$0.36	N/A	N/A
8/4/2025	Q2 2025	KRYS Krystal Biotech	$1.08	$1.29	+$0.21	$1.29	$95.42 million	$96.04 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AAPG Ascentage Pharma Group International	N/A	N/A	N/A	N/A	N/A
ACAD ACADIA Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
GPCR Structure Therapeutics	N/A	N/A	N/A	N/A	N/A
KRYS Krystal Biotech	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AAPG Ascentage Pharma Group International	1.31	1.54	1.53
ACAD ACADIA Pharmaceuticals	N/A	2.91	2.83
GPCR Structure Therapeutics	N/A	20.48	20.48
KRYS Krystal Biotech	N/A	9.68	9.33

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AAPG Ascentage Pharma Group International	N/A
ACAD ACADIA Pharmaceuticals	96.71%
GPCR Structure Therapeutics	91.78%
KRYS Krystal Biotech	86.29%

Insider Ownership

Company	Insider Ownership
AAPG Ascentage Pharma Group International	N/A
ACAD ACADIA Pharmaceuticals	26.50%
GPCR Structure Therapeutics	5.60%
KRYS Krystal Biotech	13.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AAPG Ascentage Pharma Group International	600	92.96 million	N/A	N/A
ACAD ACADIA Pharmaceuticals	510	168.71 million	124.00 million	Optionable
GPCR Structure Therapeutics	136	57.60 million	54.37 million	Optionable
KRYS Krystal Biotech	210	28.94 million	24.98 million	Optionable

GPCR, AAPG, KRYS, and ACAD Headlines

Recent News About These Companies

Price T Rowe Associates Inc. MD Has $74.08 Million Holdings in Krystal Biotech, Inc. $KRYS

August 28 at 5:06 AM | marketbeat.com

1832 Asset Management L.P. Takes $24.52 Million Position in Krystal Biotech, Inc. $KRYS

August 26 at 5:23 AM | marketbeat.com

185,550 Shares in Krystal Biotech, Inc. $KRYS Acquired by T. Rowe Price Investment Management Inc.

August 26 at 4:49 AM | marketbeat.com

Krystal Biotech halts cancer drug trial

August 25 at 1:13 PM | beckershospitalreview.comB

Chardan Capital Cuts Krystal Biotech (NASDAQ:KRYS) Price Target to $216.00

August 24, 2025 | marketbeat.com

Krystal Biotech's (KRYS) Buy Rating Reaffirmed at HC Wainwright

August 24, 2025 | marketbeat.com

Advantage Alpha Capital Partners LP Buys New Holdings in Krystal Biotech, Inc. $KRYS

August 24, 2025 | marketbeat.com

HC Wainwright Reiterates "Buy" Rating for Krystal Biotech (NASDAQ:KRYS)

August 24, 2025 | americanbankingnews.com

Aberdeen Group plc Lowers Stake in Krystal Biotech, Inc. $KRYS

August 23, 2025 | marketbeat.com

Russell Investments Group Ltd. Buys 37,336 Shares of Krystal Biotech, Inc. $KRYS

August 23, 2025 | marketbeat.com

A Glimpse Into The Expert Outlook On Krystal Biotech Through 10 Analysts

August 22, 2025 | benzinga.com

Krystal Biotech: A "Strong Buy" Despite KB707 Melanoma Tumor Targeting Update

August 22, 2025 | seekingalpha.com

Krystal Biotech price target lowered to $216 from $219 at Chardan

August 22, 2025 | msn.com

Krystal Cuts Melanoma Study of Viral Immunotherapy as FDA ‘Uncertainty’ Muddies Approval Pathway

August 22, 2025 | biospace.comB

Connor Clark & Lunn Investment Management Ltd. Buys New Position in Krystal Biotech, Inc. $KRYS

August 22, 2025 | marketbeat.com

Krystal Biotech says prioritizing inhaled KB707, pauses enrollment in OPAL-1

August 22, 2025 | msn.com

Krystal Biotech adjusts pipeline to prioritize inhaled antitumor agent

August 22, 2025 | msn.com

Krystal Biotech Provides Development Update on Inhaled KB707 for Non-Small Cell Lung Cancer Treatment

August 21, 2025 | quiverquant.comQ

Krystal Biotech Announces Update on Development Plans for Oncology Program KB707 and Prioritization of Inhaled KB707 for the Treatment of Non-Small Cell Lung Cancer

August 21, 2025 | globenewswire.com

Deutsche Bank AG Has $3.92 Million Stake in Krystal Biotech, Inc. $KRYS

August 20, 2025 | marketbeat.com

Invesco Ltd. Reduces Position in Krystal Biotech, Inc. $KRYS

August 19, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GPCR, AAPG, KRYS, and ACAD Company Descriptions

Ascentage Pharma Group International NASDAQ:AAPG

$41.13 -0.27 (-0.65%)

As of 02:15 PM Eastern

Ascentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.

ACADIA Pharmaceuticals NASDAQ:ACAD

$26.23 -0.34 (-1.28%)

Closing price 04:00 PM Eastern

Extended Trading

$26.22 0.00 (-0.02%)

As of 05:36 PM Eastern

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Structure Therapeutics NASDAQ:GPCR

$19.14 +0.14 (+0.74%)

Closing price 04:00 PM Eastern

Extended Trading

$19.12 -0.02 (-0.10%)

As of 05:27 PM Eastern

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Krystal Biotech NASDAQ:KRYS

$150.76 +3.12 (+2.11%)

Closing price 04:00 PM Eastern

Extended Trading

$150.85 +0.09 (+0.06%)

As of 05:36 PM Eastern

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time